Carmustine Implants for the Treatment of Newly Diagnosed High-Grade Gliomas

Dec 20, 2007PharmacoEconomics

Cost-effectiveness of carmustine implants for treating newly diagnosed aggressive brain tumors

AI simplified

Abstract

Surgery with the implantation of BCNU-W followed by radiotherapy costs £54,500 per additional QALY gained compared to surgery plus radiotherapy alone.

  • Probabilistic sensitivity analysis indicates a <10% probability that BCNU-W would be considered cost effective at a threshold of £30,000 per QALY.
  • The incremental cost effectiveness of BCNU-W remained above £30,000 per QALY across all analyses.
  • The study highlights the economic implications of using BCNU-W in treating newly diagnosed high-grade gliomas.
  • Findings suggest that BCNU-W is unlikely to be a cost-effective healthcare resource compared to standard treatment options.

AI simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free